JP2005500981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500981A5 JP2005500981A5 JP2002557409A JP2002557409A JP2005500981A5 JP 2005500981 A5 JP2005500981 A5 JP 2005500981A5 JP 2002557409 A JP2002557409 A JP 2002557409A JP 2002557409 A JP2002557409 A JP 2002557409A JP 2005500981 A5 JP2005500981 A5 JP 2005500981A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- kit
- pharmaceutically acceptable
- amount
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- -1 rodenosin Chemical compound 0.000 claims 20
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 15
- 239000011780 sodium chloride Substances 0.000 claims 15
- 239000003443 antiviral agent Substances 0.000 claims 13
- 208000005721 HIV Infections Diseases 0.000 claims 11
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 claims 11
- 238000002648 combination therapy Methods 0.000 claims 8
- 238000007920 subcutaneous administration Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- KYRSNWPSSXSNEP-ZRTHHSRSSA-N (4R,5S,6S,7R)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one Chemical compound NC1=CC=CC(CN2C(N(CC=3C=C(N)C=CC=3)[C@H](CC=3C=CC=CC=3)[C@H](O)[C@@H](O)[C@H]2CC=2C=CC=CC=2)=O)=C1 KYRSNWPSSXSNEP-ZRTHHSRSSA-N 0.000 claims 4
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-3H-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 claims 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 4
- ATCRIOJPQXDFNY-ZETCQYMHSA-N 6-CHLORO-2-(1-FURO[2,3-C]PYRIDIN-5-YL-ETHYLSULFANYL)-PYRIMIDIN-4-YLAMINE Chemical compound S([C@@H](C)C=1N=CC=2OC=CC=2C=1)C1=NC(N)=CC(Cl)=N1 ATCRIOJPQXDFNY-ZETCQYMHSA-N 0.000 claims 4
- MCGSCOLBFJQGHM-SCZZXKLOSA-N Abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 4
- YMARZQAQMVYCKC-OEMFJLHTSA-N Amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims 4
- RYMCFYKJDVMSIR-RNFRBKRXSA-N Apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 claims 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N Efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 4
- MLILORUFDVLTSP-UHFFFAOYSA-N Emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 claims 4
- CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 4
- 229950005339 LOBUCAVIR Drugs 0.000 claims 4
- 229960001627 Lamivudine Drugs 0.000 claims 4
- QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims 4
- 229960000689 Nevirapine Drugs 0.000 claims 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N Preveon Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 229960000329 Ribavirin Drugs 0.000 claims 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 4
- 229960001852 Saquinavir Drugs 0.000 claims 4
- QWAXKHKRTORLEM-UGJKXSETSA-N Saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 4
- 229960001203 Stavudine Drugs 0.000 claims 4
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 4
- 229960002555 Zidovudine Drugs 0.000 claims 4
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 4
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 claims 4
- 229960004748 abacavir Drugs 0.000 claims 4
- 229960003205 adefovir dipivoxil Drugs 0.000 claims 4
- 229960001830 amprenavir Drugs 0.000 claims 4
- WREGKURFCTUGRC-POYBYMJQSA-N ddC Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims 4
- BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 4
- 229960002656 didanosine Drugs 0.000 claims 4
- 229960003804 efavirenz Drugs 0.000 claims 4
- 229960001330 hydroxycarbamide Drugs 0.000 claims 4
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 4
- 229940027318 hydroxyurea Drugs 0.000 claims 4
- 229960001936 indinavir Drugs 0.000 claims 4
- 229960000884 nelfinavir Drugs 0.000 claims 4
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 4
- 229960000311 ritonavir Drugs 0.000 claims 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 4
- 230000003612 virological Effects 0.000 claims 4
- 229960000523 zalcitabine Drugs 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25665700P | 2000-12-19 | 2000-12-19 | |
| PCT/US2001/048802 WO2002056902A2 (en) | 2000-12-19 | 2001-12-17 | Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005500981A JP2005500981A (ja) | 2005-01-13 |
| JP2005500981A5 true JP2005500981A5 (US20040106767A1-20040603-C00005.png) | 2005-04-21 |
Family
ID=22973061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002557409A Pending JP2005500981A (ja) | 2000-12-19 | 2001-12-17 | ウイルス感染を処置するためのｃｃｒ５アンタゴニストおよびｄｐ−１７８ポリペプチド |
Country Status (12)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2400553A (en) * | 2003-04-14 | 2004-10-20 | Cipla Ltd | Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof |
| RU2353357C2 (ru) * | 2003-05-16 | 2009-04-27 | Юниверсити Оф Мэрилэнд Байотекнолоджи Инститьют | Композиции для супрессии экспрессии ccr5 и способы их применения |
| WO2006055638A2 (en) | 2004-11-17 | 2006-05-26 | Abgenix, Inc. | Fully human monoclonal antibodies to il-13 |
| AR063656A1 (es) * | 2005-11-30 | 2009-02-11 | Schering Corp | Composiciones que comprenden una combinacion de antagonistas de ccr5 y cxcr4 |
| WO2007065007A2 (en) * | 2005-12-01 | 2007-06-07 | Government Of The U.S.A., As Repersented By The Secretary, Dept. Of Health And Human Services | Treatment of viral infections |
| EP1886696A1 (en) * | 2006-08-03 | 2008-02-13 | Endotis Pharma | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins |
| WO2013127299A1 (zh) * | 2012-02-28 | 2013-09-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 用于抑制hiv的多肽及其作用靶点 |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| AU723537B2 (en) * | 1995-06-07 | 2000-08-31 | Trimeris Inc. | The treatment of HIV and other viral infections using combinatorial therapy |
| US6281331B1 (en) * | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| US6387930B1 (en) * | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| US6689765B2 (en) * | 1999-05-04 | 2004-02-10 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| HUP0202734A3 (en) * | 1999-05-04 | 2003-11-28 | Schering Corp | Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy |
| IL145742A0 (en) * | 1999-05-04 | 2002-07-25 | Schering Corp | Piperidine derivatives useful as ccr5 antagonists |
-
2001
- 2001-06-11 US US10/168,295 patent/US20050065319A1/en not_active Abandoned
- 2001-12-17 HU HU0302241A patent/HUP0302241A3/hu unknown
- 2001-12-17 JP JP2002557409A patent/JP2005500981A/ja active Pending
- 2001-12-17 BR BRPI0116253-5A patent/BR0116253A/pt not_active IP Right Cessation
- 2001-12-17 CA CA002431919A patent/CA2431919A1/en not_active Abandoned
- 2001-12-17 AR ARP010105840A patent/AR031931A1/es unknown
- 2001-12-17 CN CNA01820919XA patent/CN1481251A/zh active Pending
- 2001-12-17 EP EP01993303A patent/EP1385534A2/en not_active Withdrawn
- 2001-12-17 MX MXPA03005526A patent/MXPA03005526A/es unknown
- 2001-12-17 WO PCT/US2001/048802 patent/WO2002056902A2/en not_active Application Discontinuation
-
2003
- 2003-06-11 ZA ZA2003/04560A patent/ZA200304560B/en unknown
- 2003-06-18 NO NO20032769A patent/NO20032769L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2238277T3 (es) | Terapia anti-vih con una combinacion de un interferon alfa-pegilado y un antagonista de ccr5. | |
| JP2021063088A5 (US20040106767A1-20040603-C00005.png) | ||
| RU2329050C2 (ru) | Комбинация ингибиторов цитохром-р450-зависимых протеаз | |
| ES2844629T3 (es) | Tratamiento de la infección por el virus de la hepatitis delta | |
| CA2908313A1 (en) | Hepatitis c viral infection treatment using a combination of compounds | |
| EP0252290A2 (en) | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof | |
| RU2003130058A (ru) | Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона | |
| CN106535895B (zh) | 丁型肝炎病毒感染的治疗 | |
| JP2005527547A5 (US20040106767A1-20040603-C00005.png) | ||
| JP2005500981A5 (US20040106767A1-20040603-C00005.png) | ||
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 | |
| US6635646B1 (en) | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy | |
| JP2003525907A (ja) | Ｈｉｖ免疫アジュバント治療 | |
| CZ340399A3 (cs) | Farmaceutický prostředek | |
| RU2203047C2 (ru) | Композиция для снижения содержания церамидов | |
| EP1385534A2 (en) | Ccr5 antagonist and dp-178 polypeptide for treating viral infections | |
| EP0218453B1 (en) | Improved antiinflammatory compositions and methods | |
| CN112996517A (zh) | 预防hiv的整合酶抑制剂 | |
| CA2504665A1 (en) | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia | |
| RU2004121687A (ru) | Композиции, содержащие эпотилоны, и их применение для лечения карциноидного синдрома | |
| WO2007013677A1 (ja) | インターフェロン作用物質の活性増強剤 | |
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| WO2008041882A1 (fr) | Procédé pour agir sur les virus au moyen d'une substance à base de 2,8-dithioxo-1h- pyrano[2,3-d;6,5-d'] dipyrimidine et de leurs analogues 10-aza (et variantes) | |
| RU2002126216A (ru) | Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени | |
| JP2005531589A5 (US20040106767A1-20040603-C00005.png) |
